Creso Pharma Limited advised that Non- Executive Director, Dr. James Ellingford has resigned effective immediately. Dr. Ellingford will be replaced by Mr. Peter Hatfull, commencing as Non-Executive Director from 30 November 2022. Mr. Hatfull has over 40 years' experience in senior executive and Board positions with Australian and international companies.

He has an extensive skill set, which covers business optimisation, strategic planning, corporate governance capital raising and group restructuring capabilities. He is a professional director and is currently an independent director and chairman of several listed and unlisted companies. Mr. Hatfull graduated as a Chartered Accountant in the United Kingdom, where he worked for Coopers and Lybrand (now PriceWaterhouseCoopers) and subsequently moved to Africa, where he spent eight years in Malawi, prior to moving to Australia.

The Company will leverage Mr. Hatfull's extensive expertise as it progresses its strategy of assembling a strategic portfolio of businesses and brands that have complementary strengths across manufacturing, processing, formulation, sales and distribution.